Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasCellular TherapyHodgkin LymphomaIndolent LymphomasTransplantationDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapyChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaHodgkin LymphomaMantle Cell LymphomaNHL, B-Cell Type, Burkitt's LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C81.-C82.-C82.7C82.9C83.0C83.1C83.3C83.7C84.4C88.0-C91.0-C91.1-MeSHLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellLymphoma, T-Cell, PeripheralPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceIXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)MOSU(1/2/60), B-NHL, C1 (PID2105) -|- C2 (PID2106) -|- C3+ (PID2107)ChemotherapyChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMethylprednisoloneMosunetuzumabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMethylprednisoloneMosunetuzumabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMethylprednisoloneMosunetuzumabRituximabChemo-substanceCarboplatinCarmustineCisplatinCyclophosphamideCytarabineDexamethasoneEtoposideFludarabineMelphalanMethylprednisoloneMosunetuzumabRituximabNo. Substances12346 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneSupportive substanceAciclovirAllopurinolBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chloridePrednisoloneNo. Substances35678Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationRelapse therapyseveral possibleTherapy phaseInductionSalvageTherapy intentioncurativedisease controlRisksAnemia Hb below 8g/dlCardiotoxicityCytokine Release SyndromeDiarrheaEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHyperglycemiaHypertensionHypokalemiaHypophosphatemiaIncrease AminotransferasesInfectionsLymphopeniaNeuropathyNeutropeniaPneumoniaRenal FailureSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorBudde LEDavies AKirschey SLiu E Tessoulin BVelasquez WSDiseaseB-NHL, rezidiviert oder therapierefraktär, CD19- positiv, Lymphodepletion vor CAR T-Zell TherapieB-Non-Hodgkin-Lymphom/Hodgkin LymphomLymphom, Rezidiv oder refraktär, mit mindestens einer anthrazyklinhaltigen VortherapieNon-Hodgkin-Lymphom / Hodgkin Lymphomrezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2rezidiviertes oder refraktäres B-NHL, mindestens zwei vorherige systemische BehandlungenOriginCancer Research UK Centre, University of Southampton, UK, SABRINA StudieCity of Hope National Medical Center, Duarte, CADepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzNantes Medical University, Nantes, FranceSection of Lymphoma, M.D. Anderson Cancer Center, Houston, TXUniversity of Texas M.D. Anderson Cancer Center, HoustonProtocols in Revision 9 protocols foundProtocols under revision.DHAC - Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, Non-Hodgkin Lymphoma / Hodgkin Lymphoma. (PID2346 V1.0)ESHAP - Etoposide 40 / Cisplatin 25 / Cytarabine 2000 / Methylprednisolone 375, Non-Hodgkin Lymphoma. (PID2348 V1.0)Fludarabine 30 / Cyclophosphamide 300, B-non-Hodgkin Lymphoma, Lymphodepletion (PID2471 V2.0)Mosunetuzumab (1/2/60), B-Non-Hodgkin Lymphoma, cycle 1 (PID2105 V1.0)Mosunetuzumab 30, B-Non-Hodgkin Lymphoma, cycle 3+ (PID2107 V1.0)Mosunetuzumab 60, B-Non-Hodgkin lymphoma, cycle 2 (PID2106 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-DHAC - Rituximab 375 / Carboplatin 5 / Cytarabine 2000 / Dexamethasone 40, B-Non-Hodgkin's Lymphoma/Hodgkin's Lymphoma (PID2345 V1.0)Rituximab 1400, single dose subcutaneous (PID310 V2.0)
